Investor presentation for the quarter ended June 30, 2026

Date: August 12, 2026 Manager, Corporate Relationship Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001 Scrip Code: 533315 Dear Sir/Madam, Sub: Investor Presentation With reference to the subject, please find enclosed the Investor Presentation for the quarter ended June 30, 2026. Kindly take the above information on record. Thanking You, Yours faithfully, For Innovassynth Technologies (India) Limited (Formerly known as Innovassynth Investments Limited) Sameer Pakhali Company Secretary & Compliance Officer ACS 55746 Innovassynth Technologies (India) Limited (Formerly, Innovassynth Investments Limited) Registered office: Corporate Office: Old Mumbai–Pune Road, TCG International Biotech Park, Khopoli – 410 203, India. 2nd Floor, Genesis Square, Phone: +91–2192–260100 Hinjewadi Phase – II, Email: itil@innovassynth.com Pune – 411 057, India. CIN: L67120MH2008PLC178923 Phone: +91–20–61921000 www.innovassynth.com Investor Presentation Q1FY27 12-August-2026 Disclaimer “This presentation has been prepared by Innovassynth Technologies (India) Limited (“Company”) (formerly known as Innovassynth Investments Limited). The presentation aims to cover key financial and business highlights. This presentation and some statements herein may be forward-looking statements and may not be based on historical information or facts and may be expressed in good faith and in the Company’s management’s opinion reasonable, including those relating to the Company’s general business plans and strategy, its growth prospects and its competitive and regulatory environment. These statements are inherently subject to a variety of risks, uncertainties, and assumptions that could cause actual results to differ materially from those projected based on risks relating to the execution, global supply chain, technological developments, geopolitical developments, etc. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. This presentation does not aim to offer, and should not be viewed as providing, a complete or comprehensive assessment of the Company’s business, financial performance, operating results, market position, or prospects. Furthermore, this presentation is not an offer, solicitation, or invitation to buy or subscribe for any securities of the Company.” Executive Summary and Financials Executive Summary Performance Update and Outlook • Despite continued logistics-related challenges, we delivered an improvement in revenue and EBIDTA during the quarter, with margins improving both sequentially and year-on-year. • Customer demand remains healthy, supported by continued business from existing customers and new business opportunities. • The order book stood at Rs 165 crore as of 30th June 2026, providing healthy revenue visibility for the coming quarters. • Several customer molecules are progressing through different stages of development and commercialization, with some programs moving closer to commercial production. This progress has the potential to translate into additional volumes and contribute to future revenue growth. • With improving operating performance, a healthy order book and continued progress across customer programs, we remain confident of sustained improvement in business performance. Strong execution and customer demand continue to drive profitability improvement and support future growth visibility. Executive Summary Execution Highlights & Growth Drivers • Life Sciences capacity expansion remains on track, with the planned addition expected to double capacity and support anticipated growth in CRDMO demand. • A strong quality track record was maintained through successful customer audits with no major observations, reinforcing the robustness of our quality systems and compliance framework. • CRDMO customer engagement in Lifesciences continues to strengthen, with ongoing projects, repeat business and a healthy pipeline of new opportunities reflecting strong execution capabilities and customer confidence. • A diversified customer base across the USA and Europe, supported by a robust project pipeline, provides a balanced platform for sustainable growth and reduces geographic concentration risk. • Operational efficiency initiatives are progressing well, improving cost competitiveness and margins, while capacity expansion, strong customer relationships and a healthy CRDMO pipeline provide good visibility for sustained medium- term growth. With capacity expansion progressing as planned, a strong quality track record, deepening customer engagement and a healthy project pipeline, the Company remains well positioned to deliver sustainable growth and improved profitability over the medium term. Strategic Growth & Business Development Highlights Open Order Book Amount in INR Crores Life Sciences Specialty Chemicals CDMO Grand Total INR ~84 INR ~15 INR ~66 INR ~165 Major orders from USA/EU Strong portfolio and Confirmed requirements based companies, with custom product shared by large global additional orders expected company Key Focus Areas Dedicated focus on Lifesciences and Spec Chem, custom and portfolio products with a defined cadence Effective order execution and scale-up to improve process efficiency and operational excellence Successful completion of several audits could result into improved customer confidence Audit Approvals Profit and Loss Statement Particulars Quarter Ended Year Ended 30 June-2026 31-Mar-2026 30-June-2025 31-Mar-2026 Revenue from operations 5,599 5,083 1,227 10,235 Operating Expenses (4,102) (4,455) (2,780) (12,677) EBIDTA 1,497 628 (1,553) (2,442) EBIDTA Margin (%) 27% 12% -127% -24% Depreciation and Amortisation (200) (197) (195) (788) Finance Cost (200) (223) (135) (723) Other Income 19 12 9 61 Profit/(loss) before exceptional items and tax 1,116 221 (1,875) (3,892) Exceptional items - 11 (0) 82 Profit/(loss) before tax 1,116 210 (1,875) (3,974) Tax expenses/(credit) 442 (985) (8) (1,095) PAT 674 1,195 (1,867) (2,879) PAT Margin % 12% 24% -152% -28% Other Comprehensive Income - 15 - 30 Total Comprehensive Income 674 1,210 (1,867) (2,848) Diluted EPS (INR) 0.80 1.58 (2.47) -3.82 Amount in INR Lakhs 7 Company Overview Business Model Innovassynth has 3 business units Contract Research Life Sciences & Nucleosides Specialty Chemicals Development and Manufacturing Exports Led Business : ~90% of revenue from global geographies with key focus on USA & EU Our Life Sciences & Specialty Chemicals segments focus on developing niche products for customers, resulting in higher profit margins State of the art manufacturing facility 9 multipurpose manufacturing plants built to handle a wide range Integrated Manufacturing Facility of chemical processes and production scales at Khopoli, near Mumbai, India CRDMO - Our comprehensive CRDMO services, from concept to commercialization • Custom Research • 50+ highly qualified scientists specializing in specialty • Contract Manufacturing intermediates, bulk chemicals for various applications • Full Time Equivalent/Fee for Service • Custom development and manufacturing as per customer requirements • Scale up to Commercial Products Innovassynth – At a Glance • Manufacturing plant in 60+ acres at Khopoli with 8 units • 60 fume hoods catering to custom • 10+ Line with total reaction Manufacturing development for FTE/FFS R&D Facility capacity of 250 KL+ Facility • Dedicated analytical lab • 50L to 10KL reactor sizes • Equipment of various • Pharmaceuticals MOC : SSR, MSGLR, • Diagnostics Glass AR • Electronics • ANF, ANFD, Centrifuge, Chemistry of Industries • Flavours and Equipment Vacuum and Rotary Possibilities Served Fragrances Tray dryers • Semiconductors • Utilities to handle large • Polymers scale and range • Oxidation, reduction, • Tota [Showing first 8,000 characters — download PDF for full document]